



1/8

FIG. 1

*Plasma concentration: time profile for
dose level 1, mean SD*

**FIG. 2**


*Plasma concentration: time profile for
dose level 2, mean SD*




2/8

FIG. 3

Plasma concentration: time profile for
dose level 3, mean SD

**FIG. 4**


Plasma concentration: time profile for
dose level 4, mean SD




3/8

FIG. 5


AUC_{total} 17-AAG and AUC_{total} 17-AG for individual patients

**FIG. 6**


Total exposure (sum of AUC_{total} 17-AAG and AUC_{total} 17-AG) for individual patients



4/8




5/8



6/8

FIG. 9


Percent reduction of serum M-spike in Patient 307.



	Baseline	Post C1	Post C2	Post C3	Post C4	Post C5	Post C6
M-Spike (g/dL)	0.39	0	0	0	0	0	0

FIG. 10

Percent reduction of serum M-spike and urine M-protein in Patient 308.




	Baseline	Post C1	Post C2	Post C3	Post C4	Post C5	Post C6
M-Spike (g/dL)	0.08	0	0	0	0	0	0
Urine M-Protein (mg/24h)	4146	634	162	182	257	207	170

7/8


FIG. 11

Percent reduction of 20S proteasome activity following dosing of bortezomib.

**FIG. 12A**

Induction of apoptosis and reduction in AKT levels in plasma cells (CD138+).

BP, P=0.08



8/8

FIG. 12B

*Induction of apoptosis and reduction in AKT
levels in plasma cells (CD138+).*

BP, P=0.03

